BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gijs M, Ramakers IHGB, Visser PJ, Verhey FRJ, van de Waarenburg MPH, Schalkwijk CG, Nuijts RMMA, Webers CAB. Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Sci Rep 2021;11:22675. [PMID: 34811435 DOI: 10.1038/s41598-021-01993-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Pellegrini M, Bergonzoni G, Perrone F, Squitieri F, Biagioli M. Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease. Genes 2022;13:2017. [DOI: 10.3390/genes13112017] [Reference Citation Analysis]
2 Crooke A, Martínez-Alberquilla I, Madrid-Costa D, Ruiz-Alcocer J. Presbyopia: An outstanding and global opportunity for early detection of pre-frailty and frailty states. Front Med (Lausanne) 2022;9:968262. [PMID: 36267611 DOI: 10.3389/fmed.2022.968262] [Reference Citation Analysis]
3 de Fisenne MA, Yilmaz Z, De Decker R, Suain V, Buée L, Ando K, Brion JP, Leroy K. Alzheimer PHF-tau aggregates do not spread tau pathology to the brain via the Retino-tectal projection after intraocular injection in mouse models. Neurobiol Dis 2022;:105875. [PMID: 36154878 DOI: 10.1016/j.nbd.2022.105875] [Reference Citation Analysis]
4 Oh I, Shin W, Ahn J, Lee J, Min J, Ahn J, Kim Y. The present and future of minimally invasive methods for Alzheimer's disease diagnosis. Toxicol Environ Health Sci . [DOI: 10.1007/s13530-022-00144-7] [Reference Citation Analysis]
5 Król-Grzymała A, Sienkiewicz-Szłapka E, Fiedorowicz E, Rozmus D, Cieślińska A, Grzybowski A. Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review). Int J Mol Sci 2022;23:10123. [PMID: 36077520 DOI: 10.3390/ijms231710123] [Reference Citation Analysis]
6 Jung DH, Son G, Kwon O, Chang K, Moon C. Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer’s Disease. Pharmaceutics 2022;14:1532. [DOI: 10.3390/pharmaceutics14081532] [Reference Citation Analysis]
7 Lin CW, Lai TT, Chen SJ, Lin CH. Elevated α-synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson's disease. Geroscience 2022. [PMID: 35484471 DOI: 10.1007/s11357-022-00576-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Romaus-Sanjurjo D, Regueiro U, López-López M, Vázquez-Vázquez L, Ouro A, Lema I, Sobrino T. Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration. Int J Mol Sci 2022;23:2486. [PMID: 35269629 DOI: 10.3390/ijms23052486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Mahaman YAR, Embaye KS, Huang F, Li L, Zhu F, Wang JZ, Liu R, Feng J, Wang X. Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention. Ageing Res Rev 2022;74:101544. [PMID: 34933129 DOI: 10.1016/j.arr.2021.101544] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]